Media coverage about Arena Pharmaceuticals (NASDAQ:ARNA) has trended somewhat positive on Wednesday, according to Accern. The research firm identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Arena Pharmaceuticals earned a news sentiment score of 0.12 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 45.8141423851936 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the media headlines that may have effected Accern’s scoring:
Shares of Arena Pharmaceuticals (ARNA) opened at $42.64 on Wednesday. The company has a market capitalization of $1,670.00, a price-to-earnings ratio of -45.36 and a beta of 1.51. Arena Pharmaceuticals has a fifty-two week low of $11.30 and a fifty-two week high of $44.50. The company has a current ratio of 4.42, a quick ratio of 4.32 and a debt-to-equity ratio of 0.27.
A number of research firms have recently weighed in on ARNA. Citigroup raised their target price on Arena Pharmaceuticals from $37.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. BidaskClub lowered Arena Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 27th. JMP Securities lifted their price target on Arena Pharmaceuticals from $36.00 to $63.00 and gave the stock an “outperform” rating in a report on Tuesday, February 20th. ValuEngine upgraded Arena Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, February 3rd. Finally, Credit Suisse Group started coverage on Arena Pharmaceuticals in a report on Wednesday, January 17th. They set an “outperform” rating and a $44.00 price target on the stock. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $45.13.
About Arena Pharmaceuticals
Arena Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn’s disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH).